Fast-Acting Insulin Aspart Versus Insulin Aspart Using a Second-Generation Hybrid Closed-Loop System in Adults With Type 1 Diabetes: A Randomized, Open-Label, Crossover Trial.
Melissa H LeeBarbora PaldusSara VogrinDale MorrisonDessi P ZaharievaJean LuHannah M JonesEmma NetzerLesley RobinsonBenyamin GrosmanAnirban RoyNatalie KurtzGlenn M WardRichard J MacIsaacAndrzej S JanuszewskiDavid Norman O'NealPublished in: Diabetes care (2021)
Faster aspart safely improved glucose control compared with IAsp in a group of adults with well-controlled type 1 diabetes using AHCL. The modest improvement was mainly related to mealtime glycemia. While the primary outcome demonstrated statistical significance, the clinical impact may be small, given an overall difference in TIR of 1.9%.